Monsanto has hired David Dooling as computational lead engineer. Dooling was previously an assistant director at the Genome Institute at Washington University. Before joining Washington University, he was an advanced engineer at ExxonMobil Research and Engineering. He holds a PhD in chemical engineering from Northwestern University and a bachelor's degree in chemical engineering from the University of Dayton.
The Biotechnology and Biological Sciences Research Council has reappointed Cambridge University professor Tom Blundell to chair of the organization for two years. He is the founder of the BBSRC and has been the president of the Science Council since 2011.
Genome British Columbia has named Rachael Ritchie as director of business development.
Ritchie previously was a molecular geneticist at the Food, Fisheries, and Aquaculture Department Research and Productivity Council in New Brunswick. She was also project manager of the International Chair in Eco-Innovation at the UniverSud Paris/University of Versailles, and an analyst in the Science Technology Policy Department at the Organization for Economic Cooperation and Development.
Sigma-Aldrich has appointed Archie Cullen to president of BioReliance, a biologics testing firm Sigma-Aldrich acquired last year. He is replacing Charles Harwood, who is retiring. Cullen was previously vice president of Sigma-Aldrich's custom manufacturing and services business unit, SAFC, and has also held positions at Life Technologies and JRH Biosciences. He holds a BS from the University of Glasgow and an MBA from Open University in the UK.
Roche's chairman, Franz Humer said that he will not stand for re-election to the board in 2014. Roche will nominate a successor in the fall of 2013. The board has decided that Humer's successor will also serve as non-executive chairman of the board. Humer joined Roche in 1995, and has served several roles including CEO and chairman of the board of directors. He holds an MBA and a doctor of law degree from the University of Innsbruck.